Coherus Oncology: Q3 Earnings Snapshot

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Coherus Oncology, Inc. (CHRS) on Monday reported a loss of $39.3 million in its third quarter.

On a per-share basis, the Redwood City, California-based company said it had a loss of 25 cents.

The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 22 cents per share.

The drug developer posted revenue of $14.3 million in the period, which also did not meet Street forecasts. Three analysts surveyed by Zacks expected $15.9 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CHRS at https://www.zacks.com/ap/CHRS